Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Operating Expenses (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Operating Expenses for 8 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses changed N/A to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $36.3 million for FY2025, 13.73% down from the prior year.
  • Operating Expenses for Q4 2025 was $1.7 million at Actinium Pharmaceuticals, down from $5.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $16.6 million in Q1 2025, with the low at $1.7 million in Q4 2025.
  • Average Operating Expenses over 5 years is $9.4 million, with a median of $9.6 million recorded in 2024.
  • The sharpest move saw Operating Expenses surged 98.13% in 2023, then tumbled 54.11% in 2025.
  • Over 5 years, Operating Expenses stood at $8.1 million in 2021, then soared by 39.9% to $11.3 million in 2022, then fell by 7.68% to $10.4 million in 2023, then increased by 20.88% to $12.6 million in 2024, then crashed by 86.34% to $1.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.7 million, $5.8 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.